ARCT

NASDAQ open

Arcturus Therapeutics Holdings

7.35 USD
▼-0.25-3.29%
盘后 9.94 0.00%
2026-11-20
市值
$214.73M
市盈率
—
EPS
-3.08
股息率
—
52 周区间
5.50 – 17.96
成交量
281.24K
Beta
2.61
目标价
23.70
52W 低 5.5052W 高 17.96
价格走势

公司简介

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi...